Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Early Simplified: A Trial to Compare the Efficacy of Standard of Care Combination Antiretroviral Therapy With a Simplified Dolutegravir Monotherapy in Patients With a Primary HIV-1 Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02551523
Recruitment Status : Active, not recruiting
First Posted : September 16, 2015
Last Update Posted : October 12, 2018
Sponsor:
Information provided by (Responsible Party):
University of Zurich

Brief Summary:
Long term toxicity of combination antiretroviral therapy (cART) is a substantial contributor to morbidity and mortality in chronically infected HIV positive individuals. To date it is still debated, whether long term nucleoside reverse transcriptase inhibitors (NRTI's) -sparing regimens are practicable or even superior compared to standard of care cART in terms of efficacy, safety and tolerability. In addition, data about efficacy of integrase inhibitor (INSTI) based monotherapy is lacking. We aim at investigating the efficacy of standard of care combination antiretroviral therapy with a simplified dolutegravir monotherapy in patients with a primary HIV-1 infection under suppressive early standard of care antiretroviral therapy. Briefly, hundred-thirty-eight patients with a documented primary HIV1- infection (PHI) will be recruited from the Zurich Primary HIV-1 Infection Study (ZHPI), which is an open label, non-randomized, observational, single-center study (http://clinicaltrials.gov, ID 5 NCT00537966). All subjects formerly underwent early cART consisting of either a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a INSTI in combination with two NRTIs at the time point of enrolment in the ZPHI and must be under a fully suppressive ART (i.e., <50 copies/ml) for at least 48 weeks at the time point of randomisation. The primary end point is the proportion of individuals with a viral failure at week 48 or before.

Condition or disease Intervention/treatment Phase
Monotherapy Dolutegravir Primary HIV Infection Treatment Efficacy Drug: Dolutegravir Drug: Standard of care combinational antiretroviral therapy Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 101 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Randomised, Controlled, Open-label, Non-inferiority Trial to Compare the Efficacy of Standard of Care Combination Antiretroviral Therapy With a Simplified Dolutegravir Monotherapy in Patients With a Primary HIV-1 Infection Under Suppressive Early Standard of Care Antiretroviral Therapy
Study Start Date : November 2016
Estimated Primary Completion Date : October 2018
Estimated Study Completion Date : February 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: Dolutegravir monotherapy
92 patients will be simplified to once daily dolutegravir monotherapy.
Drug: Dolutegravir
92 patients will be simplified to once daily dolutegravir monotherapy

Active Comparator: Standard of care combination antiretroviral therapy
46 patients will go on with standard of care combination antiretroviral therapy consisting of either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor or a integrase inhibitor in combination with two nucleoside reverse transcriptase inhibitors.
Drug: Standard of care combinational antiretroviral therapy



Primary Outcome Measures :
  1. Proportion of individuals with a viral failure [defined as ≥2 plasma viremia levels >50copies/ml at least two weeks apart] at week 48 or before. [ Time Frame: 48 weeks ]
    The study seeks primarily to determine the efficacy (i.e., proportion of patients with a viral failure [defined as ≥2 plasma viremia levels >50copies/ml at least two weeks apart] at week 48 or before) of a simplified monotherapy (i.e., DTG) compared to a standard of care HIV triple-therapy in patients with a PHI treated with early ART under long term suppressive ART for at least 48 weeks.


Secondary Outcome Measures :
  1. Quantification of latent HIV-1 reservoir by measurement of proviral DNA and cell-associated RNA at baseline (time point of randomization), and at week 48 [ Time Frame: Week48 ]
  2. Proportion of individuals with a CSF HIV-1 RNA <50copies/ml in the CSF at week 48 after treatment simplification. [ Time Frame: Week 48 ]
  3. Proportion of patients with an adverse event at week 48. [ Time Frame: Week 48 ]
  4. Proportion of patients with a severe adverse event at week 48. [ Time Frame: Week 48 ]
  5. Time to viral failure (defined as ≥2 plasma viremia levels >50copies/ml at least two weeks apart) at week 48. [ Time Frame: Week 48 ]
  6. Proportion of individuals with blips (defined as one viral load >50 and <400 copies/ml with a next viral load <50 copies/ml) at week 48. [ Time Frame: Week 48 ]
  7. Change from baseline CD4+ cell count from baseline at week 48. [ Time Frame: Week 48 ]
  8. Proportion of individuals with new onset of proximal tubular renal dysfunction at week 48. [ Time Frame: Week 48 ]
  9. Creatinine clearance change from baseline at week 48. [ Time Frame: Week 48 ]
  10. Lipidic profile changes from baseline at week 48. [ Time Frame: Week 48 ]
  11. Proportion of individuals developing a new CDC-event at week 48. [ Time Frame: Week 48 ]
  12. Proportion of individuals withdrawing consent at week 48. [ Time Frame: Week 48 ]
  13. Proportion of individuals being lost to follow-up at week 48. [ Time Frame: Week 48 ]
  14. Proportion of individuals switching assigned treatment for any cause at week 48. [ Time Frame: Week 48 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Informed Consent as documented by signature,
  • All patients ≥18 years with a documented primary HIV-infection undergoing standard of care cART (i.e., one active drug from the class of either the PIs, or the NNRTIs, or the INSTIs, in combination with two active drugs from the class of NRTIs) with no previous structured treatment interruption and with a suppressed viral load (defined as 50 copies/ml) during the previous 48 weeks,
  • Participant of the Swiss HIV Cohort Study

Exclusion Criteria:

  • Patients not willing to sign the informed consent form,
  • Presence of ≥1 major integrase inhibitor resistance associated mutation according to the Sanford algorithm1,
  • History of ≥2 consecutive plasma viremia levels >400 copies/ml at least two weeks apart,
  • Ongoing (i.e., replicating) hepatitis B virus infection,
  • Hemoglobin < 10 g/dl (men) and < 9 g/dl (women) at the time of enrolment,
  • Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product,
  • Women who are pregnant or breast feeding,
  • Intention to become pregnant during the course of the study,
  • Lack of safe contraception,
  • Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.),
  • Known or suspected non-compliance, drug or alcohol abuse,
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
  • Participation in another study with investigational drug within the 30 days preceding and during the present study,
  • Previous enrolment into the current study,
  • Enrolment of the investigator, his/her family members, employees and other dependent persons.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02551523


Locations
Layout table for location information
Switzerland
University Hospital Zurich, University of Zurich
Zurich, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Investigators
Layout table for investigator information
Principal Investigator: Dominique L Braun, MD Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich

Layout table for additonal information
Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT02551523     History of Changes
Other Study ID Numbers: KEK-ZH-Nr. 2015-0288
First Posted: September 16, 2015    Key Record Dates
Last Update Posted: October 12, 2018
Last Verified: October 2018

Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Anti-Retroviral Agents
Dolutegravir
Antiviral Agents
Anti-Infective Agents
HIV Integrase Inhibitors
Integrase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents